RecruitingNot ApplicableNCT06715306

Intravenous Versus Oral Treatment of the Main Acute Infections

Intravenous Versus Oral Treatment of the Main Acute Infections in Emergency Departments


Sponsor

University of Southern Denmark

Enrollment

4,000 participants

Start Date

Jan 15, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Patients admitted to the hospital with acute infections are often treated with intravenous (IV) antibiotics. Around 70% of these infections fall into three categories: respiratory tract infections, urinary tract infections, and cellulitis. A Danish study found that 76% of patients admitted with suspected community-acquired pneumonia and treated with antibiotics received them intravenously. Based on an extrapolated estimate from an unpublished local survey, approximately 50,000 patients in Denmark are admitted each year for infections and treated with IV antibiotics. The average hospital stay for these patients is 5.9 days, resulting in a total of 295,000 hospital days annually, accounting for about 7% of total hospital admissions in Denmark. This represents an annual cost of 2.3 billion DKK. While some patients need hospitalization due to their overall health or other serious conditions, others remain hospitalized primarily to receive IV antibiotics. Expanding the use of oral antibiotics in emergency departments should be pursued only if it can demonstrate comparable efficacy and safety to IV administration. Therefore this study will investigate the efficiency of primarily oral antibiotics in acutely admitted patients with proven or suspected infections. Additionally, the investigators will evaluate the safety of oral regimen for these patients.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Suspected respiratory tract infection, urinary tract infection, or cellulitis by the attending physician
  • Planned or initiated intravenous antibiotic treatment

Exclusion Criteria9

  • if received more than two doses of intravenous antibiotics;
  • systolic blood pressure \<90 mmHg;
  • nausea and/or vomiting in more than one short-term instance during the last 2 days;
  • suspected significantly reduced gastrointestinal absorption;
  • confirmed plasma-lactate \> 2;
  • pregnant or nursing;
  • unable to give informed consent;
  • severe immunodeficiency;
  • urgent vital treatment needed.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHEROral treatment

Patients randomized to oral treatment will commence the oral treatment immediately. The oral treatment is based on specially developed treatment suggestions developed by microbiologists and specialists in infectious diseases from the participating regions, and in respect with local treatment guidelines (detailed described in the protocol).


Locations(7)

Sygehus Sønderjylland

Aabenraa, Southern Denmark, Denmark

Bispebjerg and Frederiksberg Hospital

Copenhagen, Denmark

Nordsjællands Hospital

Copenhagen, Denmark

Esbjerg and Grindsted Sygehus

Esbjerg, Denmark

Herlev and Gentofte Hospital

Herlev, Denmark

Amager and Hvidovre Hospital

Hvidovre, Denmark

Sygehus Lillebælt

Kolding, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06715306


Related Trials